University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3A-15-1


PHII-133: Part A: A Multi-Institutional Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal. Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Syma Iqbal, M.D.
Other Trial Staff:  Ramona Lujan, R.N., Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Xiomara Menendez, Coordinator, Noureddine Miloud, D.M., Noureddine Miloud, D.M., Arthur Alvarez, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.